G
Giulia Pasello
Researcher at University of Padua
Publications - 158
Citations - 2672
Giulia Pasello is an academic researcher from University of Padua. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 113 publications receiving 1597 citations.
Papers
More filters
Journal Article
Pemetrexed plus Carboplatin or Cisplatin as Neoadjuvant Treatment of Operable Malignant Pleural Mesothelioma (MPM)
Giulia Pasello,Giuseppe Marulli,Valentina Polo,Cristiano Breda,Laura Bonanno,L. Loreggian,Federico Rea,Adolfo Favaretto +7 more
TL;DR: AC and AP are active and feasible neoadjuvant regimens for malignant pleural mesothelioma and the lower tolerability to AP treatment could impair the clinical condition of patients undergoing surgery.
Book ChapterDOI
Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma
Giulia Pasello,Adolfo Favaretto +1 more
TL;DR: Despite the extraction, import and marketing of the mineral were banned in most of the industrialized nations, the epidemiologic data foresee a sharp rise of MPM incidence and mortality in the next fifteen years because of the long lag time from exposure to clinical evidence.
Journal ArticleDOI
Lobectomy With Artery Reconstruction and Pneumonectomy for Non-Small Cell Lung Cancer: A Propensity Score Weighting Study.
Marco Schiavon,Giovanni Maria Comacchio,Marco Mammana,Eleonora Faccioli,Francesca Stocca,Dario Gregori,Giulia Lorenzoni,Andrea Zuin,Samuele Nicotra,Giulia Pasello,Fiorella Calabrese,Andrea Dell’Amore,Federico Rea +12 more
TL;DR: In this article, a comparison between pneumonectomy and pulmonary artery reconstructions showed a higher 30-day and 90-day (P =.02) mortality rate in the pneumoneectomy group, together with a higher incidence of major complications, and overall 5-year survival (41.9% vs 35.6% respectively).
Journal ArticleDOI
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
Lorenzo Belluomini,Lorenzo Calvetti,Alessandro Inno,Giulia Pasello,Elisa Roca,Emanuela Vattemi,Antonello Veccia,Jessica Menis,Sara Pilotto +8 more
TL;DR: Following the recent therapeutic innovations, the available literature data about SCLC management is reviewed, with a focus on current unmet needs and potential predictive factors, and the role of radiotherapy is reviewed.
Journal Article
Epirubicin plus Paclitaxel Regimen as Second-line Treatment of Patients with Small-cell Lung Cancer
Giulia Pasello,Paolo Carli,Fabio Canova,Laura Bonanno,Valentina Polo,G. Zago,Loredana Urso,Pierfranco Conte,Adolfo Favaretto +8 more
TL;DR: Epirubicin with paclitaxel is an active and tolerable second-line regimen in patients with SCLC.